Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.81 and traded as high as $0.85. Seres Therapeutics shares last traded at $0.83, with a volume of 1,538,519 shares traded.
Analysts Set New Price Targets
A number of brokerages have issued reports on MCRB. Chardan Capital restated a "buy" rating and set a $1.25 price target on shares of Seres Therapeutics in a research note on Wednesday, November 13th. StockNews.com lowered Seres Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, November 27th. Canaccord Genuity Group reiterated a "buy" rating and set a $10.00 price target on shares of Seres Therapeutics in a research note on Thursday, November 14th. Finally, JPMorgan Chase & Co. cut Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $5.08.
Get Our Latest Report on Seres Therapeutics
Seres Therapeutics Stock Up 1.5 %
The company has a market capitalization of $143.98 million, a price-to-earnings ratio of -3.67 and a beta of 2.07. The business's 50-day moving average is $0.82 and its 200-day moving average is $0.90.
Institutional Trading of Seres Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC increased its holdings in Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock valued at $56,000 after buying an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC increased its stake in Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock worth $93,000 after buying an additional 22,250 shares in the last quarter. State Street Corp raised its stake in Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after purchasing an additional 43,700 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Seres Therapeutics in the second quarter valued at about $64,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics in the 2nd quarter valued at about $92,000. 59.34% of the stock is owned by institutional investors and hedge funds.
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Featured Stories
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
